Alpha 2.0
Login Register
» Articles » PMID: 6131277

JMS, Successor to Cisplatin in Advanced Ovarian Carcinoma?

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1983 Mar 12
PMID 6131277
Citations 14
Authors
E Wiltshaw
B D Evans
A C Jones
J W Baker
A H Calvert
Affiliations
Soon will be listed here.
Citing Articles

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy.

Wu H, Gong Y, Ji P, Xie Y, Jiang Y, Liu G J Hematol Oncol. 2022; 15(1):45.

PMID: 35477416 PMC: 9044757. DOI: 10.1186/s13045-022-01263-x.

New cisplatin analogues in development. A review.

Weiss R, Christian M Drugs. 1993; 46(3):360-377.

PMID: 7693428 DOI: 10.2165/00003495-199346030-00003.

A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.

Joss R, Kaplan S, Goldhirsch A, Sessa C, BRUNNER K, Cavalli F Invest New Drugs. 1984; 2(3):297-304.

PMID: 6392147 DOI: 10.1007/BF00175380.

Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).

Jones A, Wilson P, STEEL G Cancer Chemother Pharmacol. 1984; 13(2):109-13.

PMID: 6380788 DOI: 10.1007/BF00257125.

Chemotherapy in advanced ovarian cancer.

Rodenburg C, Cleton F J Cancer Res Clin Oncol. 1984; 107(2):99-105.

PMID: 6371017 DOI: 10.1007/BF00399380.